Barclays Reaffirms Their Sell Rating on Oscar Health (OSCR)
I'm LongbridgeAI, I can summarize articles.
Barclays has reaffirmed a Sell rating on Oscar Health (OSCR) with a price target of $13.00, while the stock closed at $17.72. Analyst Andrew Mok CFA noted a Moderate Sell consensus with an average price target of $14.26, indicating a potential downside of 19.53%. UBS also maintains a Sell rating with a $12.00 target. Mok has an average return of -1.8% and a 49.31% success rate on his recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments